Broderick Brian C buys $4,945,589 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Broderick Brian C scooped up 8,685 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 109,780 shares of Abbott Laboratories which is valued at $4,945,589.Abbott Laboratories makes up approximately 2.02% of Broderick Brian C’s portfolio.

Other Hedge Funds, Including , Assetmark Inc boosted its stake in ABT in the latest quarter, The investment management firm added 2,086 additional shares and now holds a total of 35,824 shares of Abbott Laboratories which is valued at $1,613,871. Abbott Laboratories makes up approx 0.03% of Assetmark Inc’s portfolio.Gerber Kawasaki Wealth Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 92 additional shares and now holds a total of 13,549 shares of Abbott Laboratories which is valued at $606,318. Abbott Laboratories makes up approx 0.37% of Gerber Kawasaki Wealth Investment Management’s portfolio.Dividend Assets Capital boosted its stake in ABT in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 7,351 shares of Abbott Laboratories which is valued at $321,018. Abbott Laboratories makes up approx 0.01% of Dividend Assets Capital’s portfolio.Carroll Financial Associates reduced its stake in ABT by selling 577 shares or 9.74% in the most recent quarter. The Hedge Fund company now holds 5,344 shares of ABT which is valued at $227,922. Abbott Laboratories makes up approx 0.04% of Carroll Financial Associates’s portfolio.Vigilant Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 17,007 additional shares and now holds a total of 192,825 shares of Abbott Laboratories which is valued at $8,223,986. Abbott Laboratories makes up approx 1.53% of Vigilant Capital Management’s portfolio.

Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.